Clinical Trial Update: BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of BTZ-043 evaluated safety, tolerability, and early bactericidal activity in pulmonary tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Other Specified Pulmonary Tuberculosis
• Pulmonary Tuberculosis

Drugs mentioned

• BTZ-043 (BTZ-043)

Snippet

Sponsor: Michael Hoelscher | Conditions: Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis | Phase 1, Phase 2 | Status: COMPLETED